Cover Image
市場調查報告書

創傷性腦損傷:開發平台分析

Traumatic Brain Injury - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213123
出版日期 內容資訊 英文 252 Pages
訂單完成後即時交付
價格
Back to Top
創傷性腦損傷:開發平台分析 Traumatic Brain Injury - Pipeline Review, H2 2017
出版日期: 2017年07月11日 內容資訊: 英文 252 Pages
簡介

創傷性腦損傷,是來自外部的機械性力量造成腦功能的障礙而引發的狀態。通常是對頭部和身體加以打擊和衝擊而產生。有頭痛、暈眩、噁心和嘔吐、心情的變化、疲勞和睡意、睡眠障礙、記憶障礙、集中力缺乏等症狀。治療包含利尿劑、抗痙攣藥、昏睡誘發藥等。

本報告提供創傷性腦損傷的治療藥之開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

創傷性腦損傷概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機別關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機別

開發治療藥的企業

  • ALSP, Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Athersys, Inc.
  • BHR Pharma, LLC
  • Cognosci, Inc.
  • Euroscreen S.A.
  • Grupo Ferrer Internacional, S.A.
  • Karyopharm Therapeutics, Inc.
  • kyorin製藥
  • Levolta Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Lpath, Inc.
  • Luc Therapeutics, Inc.
  • MandalMed, Inc.
  • Mapreg S.A.S.
  • Neuralstem, Inc.
  • Neuren Pharmaceuticals Limited
  • NeuroHealing Pharmaceuticals Inc.
  • NeuroNascent, Inc.
  • Neuronax SAS
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novogen Limited
  • Omeros Corporation
  • PharmatrophiX, Inc.
  • Phylogica Limited
  • Premier Biomedical Inc.
  • Prevacus, Inc.
  • QR Pharma, Inc.
  • RegeneRx Biopharmaceuticals, Inc.
  • Remedy Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • SanBio, Inc.
  • STATegics, Inc.
  • Tetra Discovery Partners LLC
  • vasopharm GmbH
  • VG Life Sciences, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (levocetirizine dihydrochloride + montelukast sodium)
  • 2-DG
  • ALP-496
  • AMRS-001
  • apomorphine hydrochloride
  • AST-001
  • AST-002
  • AVL-8168
  • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury
  • CHEC-7
  • CHEC-9
  • CNB-001
  • coenzyme Q10+ cyanocobalamin + cyclobenzaprine hydrochloride + naltrexone + pyridoxine
  • COG-1410
  • cyclosporine
  • dexamethasone acetate + melatonin
  • EPO-Variant
  • ESN-502
  • felbamate
  • FIB-117
  • glyburide
  • HBI-002
  • HBI-137
  • HBN-1
  • HBN-2
  • HPI-201
  • HPI-363
  • ibudilast
  • ICCN-100
  • JM-4
  • KPT-350
  • LB-201
  • LB-205
  • LM11A-31BHS
  • LM22A-4
  • Lpathomab
  • MAP-4343
  • Neu-2000- Drug Profile
  • ND-478
  • NNI-370
  • NNZ-2591
  • NSI-189
  • NSI-566
  • NVP-019
  • NVX-428
  • NWL-53
  • NX-210
  • PF-05285401
  • Posiphen
  • progesterone
  • PRV-002
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • R-503
  • RGN-352
  • SB-623
  • sepranolone
  • Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury
  • Small Molecule to Antagonize GPR17 for CNS Disorders
  • Small Molecules for Stroke and Traumatic Brain Injury
  • Small Molecules for Traumatic Brain Injury
  • Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases
  • Stem Cell Therapy for Central Nervous System Disorder
  • Stem Cell Therapy for CNS Disorders
  • STSE-15
  • T-094
  • TBI-121
  • TBI-122
  • TBI-123
  • trofinetide
  • UH-0113
  • UH-0213
  • VAS-203
  • VG-1177
  • VitalHeme
  • VOLT-02

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9514IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 9, 55 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Traumatic Brain Injury - Overview
  • Traumatic Brain Injury - Therapeutics Development
  • Traumatic Brain Injury - Therapeutics Assessment
  • Traumatic Brain Injury - Companies Involved in Therapeutics Development
  • Traumatic Brain Injury - Drug Profiles
  • Traumatic Brain Injury - Dormant Projects
  • Traumatic Brain Injury - Discontinued Products
  • Traumatic Brain Injury - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Traumatic Brain Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Traumatic Brain Injury - Pipeline by ALSP Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Aptinyx Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Athersys Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Biogen Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Cognosci Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H2 2017
  • Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H2 2017
  • Traumatic Brain Injury - Pipeline by Ischemix Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by MandalMed Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Mapreg SAS, H2 2017
  • Traumatic Brain Injury - Pipeline by Neuralstem Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H2 2017
  • Traumatic Brain Injury - Pipeline by Neurofx Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2017
  • Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by NoNO Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H2 2017
  • Traumatic Brain Injury - Pipeline by Omeros Corp, H2 2017
  • Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Prevacus Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by QR Pharma Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by SanBio Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by STATegics Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017
  • Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H2 2017
  • Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2017
  • Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2017
  • Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H2 2017
  • Traumatic Brain Injury - Dormant Projects, H2 2017
  • Traumatic Brain Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Traumatic Brain Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Traumatic Brain Injury - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Traumatic Brain Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top